Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer (TNBC)
Interventions: BIOLOGICAL: spartalizumab|BIOLOGICAL: LAG525|DRUG: NIR178|DRUG: capmatinib|BIOLOGICAL: MCS110|BIOLOGICAL: canakinumab
Sponsor: Novartis Pharmaceuticals